Home
In this issue
December 2, 2014

Jonathan Tobin: Defending the Right to a Jewish State

Heather Hale: Compliment your kids without giving them big heads

Megan Shauri: 10 ways you are ruining your own happiness

Carolyn Bigda: 8 Best Dividend Stocks for 2015

Kiplinger's Personal Finance editors: 7 Things You Didn't Know About Paying Off Student Loans

Samantha Olson: The Crucial Mistake 55% Of Parents Are Making At Their Baby's Bedtime

Densie Well, Ph.D., R.D. Open your eyes to yellow vegetables

The Kosher Gourmet by Megan Gordon With its colorful cache of purples and oranges and reds, COLLARD GREEN SLAW is a marvelous mood booster --- not to mention just downright delish
April 18, 2014

Rabbi Yonason Goldson: Clarifying one of the greatest philosophical conundrums in theology

Caroline B. Glick: The disappearance of US will

Megan Wallgren: 10 things I've learned from my teenagers

Lizette Borreli: Green Tea Boosts Brain Power, May Help Treat Dementia

John Ericson: Trying hard to be 'positive' but never succeeding? Blame Your Brain

The Kosher Gourmet by Julie Rothman Almondy, flourless torta del re (Italian king's cake), has royal roots, is simple to make, . . . but devour it because it's simply delicious

April 14, 2014

Rabbi Dr Naftali Brawer: Passover frees us from the tyranny of time

Greg Crosby: Passing Over Religion

Eric Schulzke: First degree: How America really recovered from a murder epidemic

Georgia Lee: When love is not enough: Teaching your kids about the realities of adult relationships

Cameron Huddleston: Freebies for Your Lawn and Garden

Gordon Pape: How you can tell if your financial adviser is setting you up for potential ruin

Dana Dovey: Up to 500,000 people die each year from hepatitis C-related liver disease. New Treatment Has Over 90% Success Rate

Justin Caba: Eating Watermelon Can Help Control High Blood Pressure

The Kosher Gourmet by Joshua E. London and Lou Marmon Don't dare pass over these Pesach picks for Manischewitz!

April 11, 2014

Rabbi Hillel Goldberg: Silence is much more than golden

Caroline B. Glick: Forgetting freedom at Passover

Susan Swann: How to value a child for who he is, not just what he does

Cameron Huddleston: 7 Financial Tasks You Should Tackle Right Now

Sandra Block and Lisa Gerstner: How to Profit From Your Passion

Susan Scutti: A Simple Blood Test Might Soon Diagnose Cancer

Chris Weller: Have A Slow Metabolism? Let Science Speed It Up For You

The Kosher Gourmet by Diane Rossen Worthington Whitefish Terrine: A French take on gefilte fish

April 9, 2014

Jonathan Tobin: Why Did Kerry Lie About Israeli Blame?

Samuel G. Freedman: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Jessica Ivins: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Kim Giles: Asking for help is not weakness

Kathy Kristof and Barbara Hoch Marcus: 7 Great Growth Israeli Stocks

Matthew Mientka: How Beans, Peas, And Chickpeas Cleanse Bad Cholesterol and Lowers Risk of Heart Disease

Sabrina Bachai: 5 At-Home Treatments For Headaches

The Kosher Gourmet by Daniel Neman Have yourself a matzo ball: The secrets bubby never told you and recipes she could have never imagined

April 8, 2014

Lori Nawyn: At Your Wit's End and Back: Finding Peace

Susan B. Garland and Rachel L. Sheedy: Strategies Married Couples Can Use to Boost Benefits

David Muhlbaum: Smart Tax Deductions Non-Itemizers Can Claim

Jill Weisenberger, M.S., R.D.N., C.D.E : Before You Lose Your Mental Edge

Dana Dovey: Coffee Drinkers Rejoice! Your Cup Of Joe Can Prevent Death From Liver Disease

Chris Weller: Electric 'Thinking Cap' Puts Your Brain Power Into High Gear

The Kosher Gourmet by Marlene Parrish A gift of hazelnuts keeps giving --- for a variety of nutty recipes: Entree, side, soup, dessert

April 4, 2014

Rabbi David Gutterman: The Word for Nothing Means Everything

Charles Krauthammer: Kerry's folly, Chapter 3

Amy Peterson: A life of love: How to build lasting relationships with your children

John Ericson: Older Women: Save Your Heart, Prevent Stroke Don't Drink Diet

John Ericson: Why 50 million Americans will still have spring allergies after taking meds

Cameron Huddleston: Best and Worst Buys of April 2014

Stacy Rapacon: Great Mutual Funds for Young Investors

Sarah Boesveld: Teacher keeps promise to mail thousands of former students letters written by their past selves

The Kosher Gourmet by Sharon Thompson Anyone can make a salad, you say. But can they make a great salad? (SECRETS, TESTED TECHNIQUES + 4 RECIPES, INCLUDING DRESSINGS)

April 2, 2014

Paul Greenberg: Death and joy in the spring

Dan Barry: Should South Carolina Jews be forced to maintain this chimney built by Germans serving the Nazis?

Mayra Bitsko: Save me! An alien took over my child's personality

Frank Clayton: Get happy: 20 scientifically proven happiness activities

Susan Scutti: It's Genetic! Obesity and the 'Carb Breakdown' Gene

Lecia Bushak: Why Hand Sanitizer May Actually Harm Your Health

Stacy Rapacon: Great Funds You Can Own for $500 or Less

Cameron Huddleston: 7 Ways to Save on Home Decor

The Kosher Gourmet by Steve Petusevsky Exploring ingredients as edible-stuffed containers (TWO RECIPES + TIPS & TECHINQUES)

Jewish World Review

Israeli researcher may have cure for Type 1 diabetes

By Maayan Jaffe





JewishWorldReview.com | / While methods of insulin administration have improved, and modes of measuring how much insulin to give are far superior to those of the 1920s, when insulin was discovered, there have been no major advancements toward a cure for Type 1 diabetes for almost a century.

Until now, Dr. Eli Lewis believes.

"Tissue damage actually plays a role in Type 1 diabetes… but it is often overlooked and under-studied," Lewis—a world-renowned expert on autoimmune disease and the director of the Clinical Islet Laboratory of the Department of Clinical Biochemistry & Pharmacology at Ben-Gurion University (BGU)—told JNS.org. "There was at least one stone that was left unturned."

In 2003, Lewis began his research into the role of inflammation in injured islets, tiny clusters of insulin-producing cells scattered throughout the pancreas. And during that time he discovered that Alpha 1 Antitrypsin (AAT), an anti-inflammatory drug based on a natural protein our bodies produce each day and generally used to treat emphysema, not only shows promise for reducing insulin dependence but in some cases can actually cure a person of Type 1 diabetes.

Type 1 diabetes plagues 25.8 million Americans of all ages, about 8.3 percent of the U.S. population, according to the National Diabetes Information Clearinghouse. A similar percentage of the Israeli population is affected, said Lewis, who added that on average 40 more Americans are diagnosed with Type 1 diabetes each day. All Type 1 diabetics require insulin treatment.


FREE SUBSCRIPTION TO INFLUENTIAL NEWSLETTER

Every weekday JewishWorldReview.com publishes what many in the media and Washington consider "must-reading". HUNDREDS of columnists and cartoonists regularly appear. Sign up for the daily update. It's free. Just click here.


The hormone insulin, produced by clusters of cells found on islets that reside in the pancreas, enables the body to remove glucose (sugar) from the blood into storage locations such as liver and muscle. These cells are the targets of an autoimmune response in Type 1 diabetes. When the cells become inflamed and ultimately malfunction, insulin can no longer be produced. In a healthy individual, the body naturally produces systemic AAT in the liver that helps repair tissue and reduces inflammation. It was recently established that AAT, although present in patients with Type 1 diabetes, does not function in its glycated form.

In three recent clinical trials that took place at BGU, the Barbara Davis Center for Childhood Diabetes at the University of Colorado School of Medicine, and the Joslin Diabetes Center (affiliated with Harvard Medical School), recently diagnosed patients received injections of functioning AAT in the form of a liquid slow-drip infusion. They basically regained the ability to fight inflammation and protect damaged cells from aberrant immune responses. Within eight to 12 weeks AAT therapy was withdrawn, and in several patients proper glucose levels were controlled without the need for insulin injections for more than two years.

Since AAT was already approved by the Food and Drug Administration (FDA), it received fast-track approval into human clinical trials in the U.S., Lewis said, noting it still will take at least another two years for AAT to receive FDA approval as an on-label treatment for Type 1 diabetes. But some physicians have been prescribing it in the meantime as an off-label treatment.

Dana Heffernan's son Zach, 11, received AAT treatment from his doctor in San Antonio, Texas. Heffernan said her son was diagnosed on Nov. 12, 2013 and received his first treatment in mid-December.

"He went from approximately 10 units of insulin per day [70 units per week] down to two units per week. So that is pretty significant. Will he ever be off insulin completely? That is my hope, but we will have to see," Heffernan said.

In another public case, which Lewis discussed, the Consul General of Israel to the Pacific Northwest, Andy David, accessed AAT for use in treating his 9-year-old daughter. She underwent once-a-week slow-drip infusions of AAT for 8 weeks. That was close to three years ago, and she has not had to have insulin since.



The treatment, however, may not be effective for all patients. Dr. Peter A. Gottlieb, professor of pediatrics and medicine at the Davis Center, led the Colorado clinical trial. He said the treatment was promising for about one-third of those who received AAT, but was less effective or even ineffective in others. He attributes this to multiple factors, including how long the person has had the disease and how much of the AAT was administered. He said another set of clinical trials is underway using larger doses. Lewis said in all trials, if one has

been diagnosed with Type 1 for more than six months "the benefits are minimal."

Gottlieb also noted that AAT is a "pretty expensive" drug, since it is extracted from human plasma. This could prove a barrier. Omni Pharmaceuticals is working on a second-generation drug, Gottlieb said, which could prove as effective and also reduce the price tag for treatment. Lewis said large-scale production of AAT would also allow for researchers to improve the drug's functionality.

The results of the most recent clinical trials will be published this March in The Journal of Clinical Endocrinology and Metabolism.

Lewis noted that researchers are still unclear as to why one gets Type 1 diabetes. While genetic factors certainly play a role, more recent studies have indicated that the disease could also be linked to stress/trauma (even psychological trauma), or could be viral. His lab has also found a way to use AAT to aid in islet transplant survival and is working on how the drug might prove useful for the treatment of Type 2 diabetes, commonly associated with diet and lifestyle factors. He cited a Swedish study that found half of patients with Type 2 diabetes to have decreased levels of circulating AAT.

Lewis will be in the U.S. in late March and early April to talk about his findings and look for additional medical research partners in the U.S. His visits will include major cities, such as San Antonio, Los Angeles, Washington, D.C., Baltimore, Philadelphia, and New York. For more information about these visits, contact your local chapter of American Associates of Ben-Gurion University of the Negev (http://www.aabgu.org/).

If one is interested in being a part of a clinical trial, ongoing studies can be found at clinicaltrials.gov. Type "diabetes" and "Antitrypsin" into the search bar.

"We're not out of the woods," said Lewis. "More than ever, there is promise. … Our team at BGU is working on this relentlessly, and we hope the upcoming visit to the US will represent a shift-in-gear to a more rapid advance."

Interested in a private Judaic studies instructor — for free? Let us know by clicking here.

Sign up for the daily JWR update. It's free. Just click here.









© 2014, JNS.org. All rights reserved.

Quantcast